C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %

Similar documents
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10

HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly

untitled

日本医師会雑誌第131巻第10号


ケイセントラ_製品情報概要_H1-4_収載_新発売


函館市_絵で見てわかる

「スウェーデン企業におけるワーク・ライフ・バランス調査 」報告書

第 14 回血管病理研究会 日時 : 平成 20 年 10 月 10 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ) CRP MPO-ANCA 125IU/l CT mpa

indd

untitled

長崎県県央保健所事業概要

untitled

II (No.2) 2 4,.. (1) (cm) (2) (cm) , (

untitled

肝臓病教室201207v2配布用.pptx

64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k

* 1 6 ( ) 20 GOT GPT ( ) 59 3 CT F D T3 *

商品リストVol09_01

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

　


PSCHG000.PS

1 Q A 82% 89% 88% 82% 88% 82%

WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH

sick contact1l

2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742

慈大呼吸器_25-1_02T_CS5.indd

中高齢者の健康・いきいきライフスタイルづくり調査

untitled

Slide 1

I

- 9 91, (2006)

A5_Catalog-US-JN_ indd

ニトロトルエン


untitled

untitled

EPSON LP-8900ユーザーズガイド

/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)

BA_kanen_QA_zenpan_kani_univers.indd

THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr B 2 NTT

BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI


高脂血症の検査

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1

2

日本呼吸器学会雑誌第44巻第6号

ph

1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61

Ⅱ　学校給食の意義と役割

橡アロマセラピー症状別処方例.PDF

無印良品 2012 自転車 カタログ

スライド 1

untitled


AD-5423_2

2 CSR -

日清製粉2013_H1_H4.indd

滋賀CSR経営モデル

untitled

C 型慢性肝炎に対するテラプレビルを含む 3 剤併用療法 の有効性 安全性等について 肝炎治療戦略会議報告書平成 23 年 11 月 28 日


untitled

untitled

A B 1.A B A B 2.A B A B 3.A

1 Blood chemistry Peripheral blood Viral marker TP 5.4 g dl WBC ml Syphilis TPAb Alb 2.7 g dl RBC ml HBsAg T. bil 2.3 mg dl Hb 11 g dl

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx

/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

Microsoft Word - 第２回海外勤務健康管理抄録の表紙他.doc

橡DI月報１７8.PDF

2

食事編_表1_4_0508

Microsoft Word - 表紙資料２－４

BIT -2-

(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12

1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR

20－121

50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH

[] 1

untitled

.\..1-4_2012PDF.p


日本呼吸器学会雑誌第48巻第6号

生化学検査 臨床検査基準値一覧 近畿大学病院 (1) 検査項目 基準値 単位 検査項目 基準値 単位 CRP mg/dl WBC /μl Na mmol/l M RBC K mmol/l F 3.86-

日本化学療法学会雑誌第56巻第1号



17-05 THUNDERBIRD SYBR qpcr Mix (Code No. QPS-201, QPS-201T) TOYOBO CO., LTD. Life Science Department OSAKA JAPAN A4196K

8 300 mm 2.50 m/s L/s ( ) 1.13 kg/m MPa 240 C 5.00mm 120 kpa ( ) kg/s c p = 1.02kJ/kgK, R = 287J/kgK kPa, 17.0 C 118 C 870m 3 R = 287J

051


DynalTransplantDiagnostic.indd

スライド 1


2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,

九州支部卒後研修会症例

Transcription:

2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up 2 46 PEG/R 1:1 PEG-IFN-2b + IFN-2b + IFN/R 90 48 24 500 (PEG-IFN-2b 250 IFN-2b 250 ) 514 (PEG-IFN-2b 258 IFN-2b 256 ) 511 (PEG-IFN-2b 257 IFN-2b 254 ) 507 (PEG-IFN-2b 254 IFN-2b 253 ) FAS 506 (PEG-IFN-2b 254 IFN-2b 252 ) IFN C PEG-IFN-2b + C034* Genotype 1b 100 kcopies/ml HCV-RNA PEG-IFN -2b 1.5 µg/kg + 46 IFN-2b 300 IU + 34 12 IFN-2b 600 IU IFN PEG-IFN -2b + IFN-2b + HCV-RNA C034 PEG-IFN-2b + HCV-RNA IFN -2b + 5 IFN-2b + 41 PEG-IFN-2b + 46 PEG-IFN-2b + IFN -2b + 1 250 500 600

2.7.6-54 C033** of 7 C034** 2 12 1 250 PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n=150 + + =10 % 46 41 92 % 85 % 74 % 46 34 78 % 68 % 56 % n 1 2.5 Genotype 1 C 20 40kg 100 kg 60 C Genotype 1Genotype 1a 1b HCV-RNA RT-PCR HCV 100 k IU/mL 60 ALT ALT 45 IU/L 60 0 - * (%)0.124 * (ng/ml)0.001 =1, 2 (-0.413) *(/mm 3 )(-0.075)2.005 * 1 365 60 12 g/dl 1,500 /mm 3 10 /mm 3 Cockcroft 51 Ccr =140 (kg) /72 (mg/dl) Ccr Ccr 0.85 110 mg/dl 110 mg/dl 126 mg/dl Hb A1c 6.5% 2 polyethylene glycol IFN IFN 30 IFN IFN 90 60 HBs 60 160 120 mmhg grade 3 601

2.7.6-54 C033* 3 of 7 30 C 90 180 IFN HCG PEG-IFN-2b IFN-2b peginterferon alfa-2binn 1.5 µg/kg 1 48 2b JAN IFN-2b 600 IU 2 6 46 3 (JAN) 6001,000 mg/1 2 48 PEG/R PEG-IFN-2b + PEG-IFN-2b 1.5g/kg 1/ 600800 1000 mg/ 48 IFN/R IFN-2b IFN-2b 600IU 6/ 3 600800 1000 mg/ 2 46 602

2.7.6-54 C033* 4 of 7 HIV IFN IL-2 C () -90 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48 4 8 12 24 Day 1) -90 1 8 15 22 29 57 85 113 141 169 197 225 253 281 309 337 365 393 421 505 2) 3) 4) 5) CT X PEGR 1 IFNR 3 a) --#-- b) --#-- c) --#-- HCG --#-- HCV-RNA HCV-RNA HCV genotype HBs f) ml 29 14 8 19 8 19 8 19 8 8 19 8 8 19 8 8 19 19 8 19 19 1 Day1a 2 baltast -GTPALPLDH 314 BUN HbA1C* CRP - * * 4 14 ctshft3ft4trab*tpoab* 5 365 dbranched DNA probe* HCV 48 e fafppivka-ii * # Day-14 1. 24 24 HCV-RNA RT-PCR 24 HCV-RNA 24 HCV-RNA IFN / 1. 24 24 HCV-RNA RT-PCR 24 HCV-RNA 24 HCV-RNA 2. 24 HCV-RNA RT-PCR HCV-RNA HCV-RNA 603

2.7.6-54 C019* 5 of 7 3. 12 12 HCV-RNA RT-PCR 12 HCV-RNA 12 HCV-RNA IFN / 4. ALT ALT ALT ALT ALT 5. ALT 24 24 ALT 24 ALT 24 ALT ALT IFN / 1. 1) 2) 3) 2. 604

2.7.6-54 C033* 6 of 7 3. 3 1 4. 4 13 0. 1. 2. 3. [FAS PPS PPS ] IFN Wilcoxon-Mann-Whitney test Mantel-Haenszel test Fisher s exact test 1. IFN 2. HCV-RNA RT-PCR HCV ALT 3. PEG-IFN-2bIFN-2b 24 HCV-RNA 1. FAS PEG/R IFN/R -10 PEG/R IFN/R 2. PPS PPS IFN 3. 24 logistic regression analysis IFN HCV-RNA RT-PCR HCV ALT 4. 24 IFN HCV-RNA RT-PCR HCV ALT 605

2.7.6-54 C033* 7 of 7 PEG/R IFN/R ALT 24 12 ALT 24 HCV-RNA HCV-RNA 24 HCV-RNA HCV-RNA 24 HCV-RNA 24 24 HCV-RNA ALT HCV-RNA ALT 24812243648 48 MedDRA 1. skewnesskurtosis 25% 75% grade 2. 606

2.7.6-8 2.7.6-9 2.7.6-55 786 272 233 15 2 22 8 514 PEG/R 258 IFN/R 256 511 PEG/R 257 IFN/R 254 3 PEG/R 1 IFN/R 2 1 1 511 PEG/R 257 IFN/R 254 48 PEG/R 20.2%52 /257 IFN/R 21.7%55 /254 / / PEG/R 8.9%23 /257 IFN/R 8.3%21 /254 PEG/R 8.9%23 /257 IFN/R 9.8%25 /254 511 PEG/R 257 IFN/R 254 511 24 19 PEG/R 6 IFN/R 13 PEG/R 2.3%6 /257 IFN/R 3.9%10 /254 / / PEG/R 0.0%0 /257 IFN/R 0.4%1 /254 607

786 * 272 15 233 2 233 22 514 PEG-IFN-2b IFN-2b 258 256 2 1 1 * 1 52 55 Hb/PLT Hb/PLT 257 /Neu 23 254 /Neu 21 Hb/PLT Hb/PLT /Neu 23 1 1 1 /Neu 25 4 2 1 48 2 48 1 1 205 1 199 9 5 2.7.6-8 PEG-IFN-2b IFN-2b ** 257 ** 254 ) 6 6 13 10 1 2 251 241 1 24 2.7.6-9 608

2.7.6-55 C033* (C033*) PEG/R IFN/R PEG-IFN-2b/ IFN-2b 6MIU 6 / 1.5 µg/kg1 / 48 2 6MIU3 / 46 600-1,000 mg/ 600-1,000 mg/ 48 48 257 254 257 100.0% 254 100.0% 24 30 11.7% 39 15.4% 0 0.0% 1 0.4% / / 16 6.2% 17 6.7% / / 11 4.3% 14 5.5% 1 0.4% 0 0.0% 1 0.4% 0 0.0% 1 0.4% 2 0.8% 0 0.0% 1 0.4% A 0 0.0% 4 1.6% 24 227 88.3% 215 84.6% 24 48 22 8.6% 16 6.3% / / 7 2.7% 4 1.6% / / 12 4.7% 11 4.3% / 1 0.4% 1 0.4% 2 0.8% 0 0.0% 48 205 79.8% 199 78.3% 257 100.0% 254 100.0% 24 6 2.3% 13 5.1% 6 2.3% 10 3.9% 0 0.0% 1 0.4% 0 0.0% 1 0.4% / / 0 0.0% 1 0.4% 24 251 97.7% 241 94.9% CHC500CSR14_1_1_4 all randomized subjects ARS Full analysis set FAS FAS Per Plotocol Set PPS FAS PPS ARS FAS ARS 514 PEG/R 258 IFN/R 256 609

ARS 514 PEG/R 258 IFN/R 256 507 PEG/R 254 IFN/R 253 7 PEG/R 4 IFN/R 3 GCP 5 PEG/R 3 IFN/R 2 2 PEG/R 1 IFN/R 1 GCP 5 IFN/R 1 / PEG/R IFN/R 3 PEG-IFN-2b 1 IFN-2b 2 IFN/R 1 PEG/R 1 ARS 514 PEG/R 258 IFN/R 256 FAS 506 PEG/R 254 IFN/R 252 FAS 8 PEG/R 4 IFN/R 4 GCP 5 PEG/R 3 IFN/R 2 2 PEG/R 1 IFN/R 1 IFN-2b 1 IFN/R 1 IFN-2b 1 IFN/R 1 FAS 506 PEG/R 254 IFN/R 252 PPS 429 PEG/R 219 IFN/R 210 PPS 77 PEG/R 35 IFN/R 42 8 PEG/R 4 IFN/R 4 2 PEG/R 1 IFN/R 1 3 PEG/R 1 IFN/R 2 17 PEG/R 6 IFN/R 11 5 PEG/R 1 IFN/R 4 70 PEG/R 32 IFN/R 38 FAS PPS ARS 507 PEG/R 254 IFN/R 253 2.7.6-56 24 PEG/R 87.8 223 /254 IFN/R 84.6%214 /253 80% 24 48 PEG/R 79.5 202 /254 IFN/R 78.3%198 /253 2 610

2.7.6-56 C033* PEG/R n= 254 IFN/R n= 253 2 114 25098.4% 24396.0% 4 1528 24596.5% 23693.3% 8 2956 24094.5% 23291.7% 12 5784 23391.7% 22689.3% 24 85168 22387.8% 21484.6% 36 169252 21082.7% 20581.0% 48 20279.5% 253 19878.3% CSR T01 2.7.6-57 24 PEG/R 600 mg 87.2 82 /94 800 mg 88.0 125 /142 1,000 mg 88.9 16 /18 IFN/R 600 mg 81.1 86 /106 800mg 86.3 113 /131 1,000 mg 93.8 15 /16 PEG/R 48 600 mg 78.7 74 /94 800 mg 78.9 112 /142 1,000 mg 88.9 16 /18 IFN/R 48 600 mg 72.6 77 /106 800 mg 82.4 108 /131 1,000 mg 81.3 13 /16 2.7.6-57 C033* PEG/R n=254 IFN/R n=253 PEG-IFN-2b/IFN-2b 1.5 µg/kg 1.5 µg/kg 1.5 µg/kg 600MIU 600MIU 600MIU 600mg 800mg 1,000mg 600mg 800mg 1,000mg 94 142 18 106 131 16 2 93 139 18 100 127 16 114 98.9% 97.9% 100.0% 94.3% 96.9% 100.0% 4 1528 91 96.8% 137 96.5% 17 94.4% 96 90.6% 124 94.7% 16 100.0% 8 2956 89 94.7% 135 95.1% 16 88.9% 93 87.7% 123 93.9% 16 100.0% 12 5784 85 90.4% 132 93.0% 16 88.9% 92 86.8% 119 90.8% 15 93.8% 24 85168 82 87.2% 125 88.0% 16 88.9% 86 81.1% 113 86.3% 15 93.8% 36 169252 77 81.9% 117 82.4% 16 88.9% 80 75.5% 110 84.0% 15 93.8% 48 74 112 16 77 108 13 253 78.7% 78.9% 88.9% 72.6% 82.4% 81.3% CSR T02 611

FAS 506 PEG/R 254 IFN/R 252 2.7.6-58 2.7.6-58 C033* 1 of 3 (C033*) PEG/R IFN/R 254 252 165 (65.0%) 164 (65.1%) [Fisher's exact test] 89 (35.0%) 88 (34.9%) p =1.0000 52.17 50.73 10.26 bae5-0.6956-0.4596-0.1444-0.0339 70 70 75% 60 59 54 51 25% 46 44 22 20 kg [Wilcoxon Mann Whit ney test] Z=-1.8359p=0.0664 65 237 (93.3%) 229 (90.9%) [Fisher's exact test] 65 17 (6.7%) 23 (9.1%) p =0.3275 63.97 63.68 10.23 11.11 0.3130 0.3460-0.2691-0.1980 96 97.2 75% 70.9 70.95 64 64.2 25% 56 55.1 43.5 40.5 [Wilcoxon-Mann-Whitn ey test] Z=-0.3238p=0.7461 60kg 94 (37.0%) 106 (42.1%) [ Mantel-Haenszel 60kg 80kg 142 (55.9%) 130 (51.6%) test] 80kg 18 (7.1%) 16 2 =1.2895df= 1 (6.3%) p=0.2561 10.11 9.31 7.62 7.30 1.3043 1.2192 1.8355 1.5863 40 38 75% 13 12 9 8 25% 5 4 0 0 [Wilcoxon-Mann-Whitn ey test] Z=-1.3991p=0.1618 1 5 (2.0%) 7 (2.8%) [ Mantel-Haenszel 1 5 50 (19.7%) 66 (26.2%) test] 5 10 89 (35.0%) 81 (32.1%) 2 =2.5baedf= 1 10 110 (43.3%) 98 (38.9%) p=0.1131 55 (21.7%) 43 (17.1%) [Fisher's exact test] 199 (78.3%) 209 (82.9%) p =0.2162 137 (53.9%) 139 (55.2%) 91 (35.8%) 81 (32.1%) [Fisher's exact test] IFN 26 (10.2%) 31 (12.3%) p =0.6160 0 (0.0%) 1 (0.4%) Genotype 1a 2 (0.8%) 0 (0.0%) [Fisher's exact test] 1b 252 (99.2%) 252 (100.0%) p =0.4990 1a1b 0 (0.0%) 0 (0.0%) 612

2.7.6-58 C033* of 3 (C033*) PEG/R IFN/R 254 252 no fibrosis 0 (0.0%) 0 (0.0%) mild fibrosis 107 (42.1%) bae (41.3%) [ Mantel-Haenszel moderate fibrosis 109 (42.9%) 114 (45.2%) test] severe fibrosis 34 (13.4%) 30 (11.9%) 2 =0.0211df= 1 staging cirrhosis 1 (0.4%) 3 (1.2%) p=0.8844 3 (1.2%) 1 (0.4%) None 0 (0.0%) 0 (0.0%) Minimal chronic 48 (18.9%) 49 (19.4%) hepatitis [ Mantel-Haenszel Mild chronic hepatitis 88 (34.6%) 89 (35.3%) test] Moderate chronic 102 (40.2%) 94 (37.3%) hepatitis 2 =0.0032df= 1 grading Severe chronic p=0.9547 13 (5.1%) 19 (7.5%) hepatitis 3 (1.2%) 1 (0.4%) 689.13 693.93 212.93 208.89-1.0699-1.1072 HCV-RNA -0.1378-0.0336 [Wilcoxon-Mann-Whitn 850 850 ey test] RT-PCR 75% 850 850 Z=0.1848p=0.8534 850 850 HCV 25% 550 540 130 110 KIU/mL300 22 (8.7%) 16 (6.3%) 300 500 31 (12.2%) 38 (15.1%) 500 850 71 (28.0%) 68 (27.0%) 850 130 (51.2%) 130 (51.6%) 114.92 11bae 70.44 63.56 1.7202 1.5080 3.6565 2.8100 433 409 ALT 75% 146 136 93.5 95 IU/L 25% 64 66 32 28 45 16 (6.3%) 16 (6.3%) 45 100 121 (47.6%) 117 (46.4%) 100 200 88 (34.6%) 96 (38.1%) 200 29 (11.4%) 23 (9.1%) [ Mantel-Haenszel test] 2 =0.0151df= 1 p=0.9023 [Wilcoxon-Mann-Whitn ey test] Z=-0.2186p=0.8269 [ Mantel-Haenszel test] 2 =0.0007df= 1 p=0.9784 613

2.7.6-58 C033* 3 of 3 (C033*) PEG/R IFN/R 254 252 14.57 14.54 1.25 1.20 0.0252 0.0648-0.2870-0.5317 [Wilcoxon-Mann-Whitn 18.2 17.4 ey test] g/dl 75% 15.5 15.4 Z=-0.3708p=0.7108 14.6 14.5 25% 13.6 13.6 11.3 11.5 2,792.16 2,741.99 1,055.42 957.84 1.7691 1.4381 4.6374 2.6332 [Wilcoxon-Mann-Whitn 8,000 6,577 /mm 3 ey test] 75% 3,235 3,196 Z=-0.3484p=0.7275 2,614 2,533.5 25% 2,042 2,065 1,376 1,486 17.20 17.14 4.73 4.67 1.0930 0.5947 1.8461-0.1922 [Wilcoxon-Mann-Whitn 39.4 32.7 /mm 3 ey test] 75% 19.6 20.45 Z=-0.0520p=0.9585 16.5 16.3 25% 13.9 13.45 10 10 CHC500CSR14_1_4_1&CSR14_1_4_6 Wilcoxon-Mann-Whitney testp=0.0664 Mantel-Haenszel testp=0.1131 2 12 24 HCV-RNA ALT 614

24 12 24 HCV-RNA 2.7.6-59 24 HCV-RNA PEG/R 47.6 121 /254 IFN/R 44.8 113 /252 2 PEG/R IFN/R 95-5.9 11.5 24 HCV-RNA PEG/R 66.9 170 /254 IFN/R 65.5 165 /252 2 PEG/R IFN/R 95-6.8 9.7 HCV-RNA PEG/R 71.7 182/254 IFN/R 69.4 175 /252 2 PEG/R IFN/R 95-5.7 10.2 12 HCV-RNA PEG/R 47.6 121 /254 IFN/R 45.6 115 /252 2 PEG/R IFN/R 95-6.7 10.7 HCV-RNA PEG/R IFN/R 95% IFN/R PEG/R PEG-IFN-2b+ IFN-2b+ PPS ARS FAS IFN HCV-RNA PEG/R IFN/R 95% PPS -7.0 11.9%ARS -5.9 11.4% IFN -6.9 10.1% HCV-RNA 2.7.6-59 HCV-RNA C033** PEG/R n= 254 IFN/R n= 252 HCV-RNA * 95% 24 n= 254 n= 252 170 (66.9%) 165 (65.5%) -6.8% 9.7% 57 (22.4%) 53 (21.0%) 27 (10.6%) 34 (13.5%) n= 254 n= 252 182 (71.7%) 175 (69.4%) -5.7% 10.2% 69 (27.2%) 70 (27.8%) 3 ( 1.2%) 7 ( 2.8%) 12 n= 254 n= 252 121 (47.6%) 115 (45.6%) -6.7% 10.7% 122 (48.0%) 122 (48.4%) 11 ( 4.3%) 15 ( 6.0%) 24 n= 254 n= 252 121 (47.6%) 113 (44.8%) -5.9% 11.5% 122 (48.0%) 120 (47.6%) 11 ( 4.3%) 19 ( 7.5%) *PEG/R -IFN/R CSR 14_2_2_1 staging grading 615

HCV-RNA RT-PCR ALT / 2.7.6-60 24 HCV-RNA IFN PEG/R 43.1 59 /137 IFN/R 46.8 65 /139 PEG/R 62.6 57 /91 IFN/R 51.9 42 /81 PEG/R 19.2 5 /26 IFN/R 19.4 6 /31 IFN 24 HCV-RNA 2.7.6-60 HCV-RNA C033** / PEG/R IFN/R HCV-RNA 254 252 *95% 59/137 (43.1%) 65/139 (46.8%) -15.4%8.0% 57/91 (62.6%) 42/81 (51.9%) -4.0%25.5% IFN 5/26 (19.2%) 6/31 (19.4%) -20.7%20.4% 0/0 (0.0%) 0/1 (0.0%) no fibrosis 0/0 (0.0%) 0/0 (0.0%) mild fibrosis 60/107 (56.1%) 55/bae (52.9%) -10.2%16.6% moderate fibrosis 50/109 (45.9%) 44/114 (38.6%) -5.7%20.2% Stagingsevere fibrosis 11/34 (32.4%) 13/30 (43.3%) -34.7%12.7% cirrhosis 0/1 (0.0%) 0/3 (0.0%) 0/3 (0.0%) 1/1 (100.0%) -100.0%-100.0% none 0/0 (0.0%) 0/0 (0.0%) minimal chronic hepatitis 20/48 (41.7%) 20/49 (40.8%) -18.7%20.4% mild chronic hepatitis 52/88 (59.1%) 46/89 (51.7%) -7.2%22.0% moderate chronic Grading 45/102 (44.1%) 41/94 (43.6%) -13.4%14.4% hepatitis severe chronic hepatitis 4/13 (30.8%) 5/19 (26.3%) -27.5%36.4% 0/3 (0.0%) 1/1 (100.0%) -100.0%-100.0% 300 13/22 (59.1%) 9/16 (56.3%) -29.0%34.7% HCV-RNA 300 500 16/31 (51.6%) 15/38 (39.5%) -11.3%35.6% RT-PCR 500 850 27/71 (38.0%) 22/68 (32.4%) -10.2%21.5% KIU/mL850 65/130 (50.0%) 67/130 (51.5%) -13.7%10.6% 10 11 26/72 (36.1%) 39/87 (44.8%) -24.0%6.5% 11 12 48/93 (51.6%) 35/85 (41.2%) -4.1%25.0% 12 13 40/73 (54.8%) 32/65 (49.2%) -11.1%22.2% mg/kg13 14 7/16 (43.8%) 6/12 (50.0%) -43.5%31.0% 14 15 0/0 (0.0%) 1/3 (33.3%) 45 5/16 (31.3%) 8/16 (50.0%) -52.2%14.7% 45 100 53/121 (43.8%) 54/117 (46.2%) -15.0%10.3% ALT 100 200 45/88 (51.1%) 42/96 (43.8%) -7.0%21.8% IU/mL 200 18/29 (62.1%) 9/23 (39.1%) -3.7%49.6% 65 6/17 (35.3%) 7/23 (30.4%) -24.6%34.3% 65 115/237 (48.5%) 106/229 (46.3%) -6.8%11.3% 94/165 (57.0%) 82/164 (50.0%) -3.8%17.7% 27/89 (30.3%) 31/88 (35.2%) -18.7%8.9% Caucasian 0/1 (0.0%) 0/0 (0.0%) Asian 121/253 (47.8%) 113/252 (44.8%) -5.7%11.7% 40 60 33/94 (35.1%) 45/106 (42.5%) -20.8%6.1% 60 80 82/142 (57.7%) 63/130 (48.5%) -2.5%21.1% kg 80 100 6/18 (33.3%) 5/16 (31.3%) -29.4%33.5% *PEG/R -IFN/R CSR14_2_2_314_2_3_714_2_5_1 616

stepwise 20% stepwise 2.7.6-611 2 HCV-RNA PEG/R staging 5%IFN/R staging grading HCV-RNA RT-PCR 5% 2.7.6-611 PEG/R FAS 0.0020 1.757 0.919 3.357 0.0882 0.213 0.067 0.678 0.0088 0.541 0.346 0.844 0.0068 0.0801 1.007 0.284 3.570 0.9916 1.815 0.480 6.861 0.3797 3.684 0.774 17.541 0.1015 0.0548 1.635 0.759 3.521 0.2091 0.424 0.111 1.620 0.2095 0.419 0.192 0.914 0.0289 15.750 5.362 46.261 <.0001 R 14 * stepwise 2.7.6-602 IFN/R FAS 0.963 0.519 1.787 0.9046 0.210 0.075 0.587 0.0029 0.479 0.269 0.853 0.0124 1.702 1.061 2.731 0.0275 0.0245 0.719 0.201 2.578 0.6129 0.414 0.125 1.366 0.1476 1.216 0.395 3.745 0.7329 18.229 5.919 56.145 <.0001 *. stepwise HCV-RNA 2.7.6-62 2.7.6-10 2 HCV-RNA 4 12 36 617

2.7.6-62 HCV-RNA C033* PEG/R n=254 IFN/R n=252 5/253 (2.0%) 16/249 ( 6.4%) 23/249 (9.2%) 31/238 (13.0%) 12 144/238 (60.5%) 124/232 (53.4%) 24 170/227 (74.9%) 165/218 (75.7%) 36 171/218 (78.4%) 162/208 (77.9%) 48 164/206 (79.6%) 155/201 (77.1%) 182/251 (72.5%) 175/245 (71.4%) 131/245 (53.5%) 127/239 (53.1%) 12 121/243 (49.8%) 115/237 (48.5%) 24 121/243 (49.8%) 113/233 (48.5%) 121/244 (49.6%) 114/237 (48.1%) (CSR 14_2_6_2) 100.0 80.0 60.0 40.0 20.0 PEG/R IFN/R 0.0 0 12 24 36 48 60 72 12 84 24 96 2.7.6-10 HCV-RNA C033* 618

HCV-RNA HCV-RNA 2.7.6-63 12 HCV-RNART-PCR 75% HCV-RNA 24 12 HCV-RNA HCV-RNA PEG/R 100%5 /5 100%18 /18 71.1%86 /121 IFN/R 75.0%12 /16 84.2%16 /19 69.9%65 /93 24 HCV-RNA PEG/R IFN/R 36.4%12 /33 40.8%20 /49 24 HCV-RNA HCV-RNA 2.7.6-63 HCV-RNA HCV-RNA C033* HCV-RNA PEG/R n=254 IFN/R n=252 n=5 n=16 2 5 (100.0%) 12 (75.0%) 0 (0.0%) 1 (6.3%) 4 12 24 36 48 (CSR 14_2_6_3_2) 0 (0.0%) 3 (18.8%) n=18 n=19 18 (100.0%) 16 (84.2%) 0 (0.0%) 3 (15.8%) 0 (0.0%) 0 (0.0%) n=121 n=93 86 (71.1%) 65 (69.9%) 34 (28.1%) 24 (25.8%) 1 (0.8%) 4 (4.3%) n=33 n=49 12 (36.4%) 20 (40.8%) 21 (63.6%) 28 (57.1%) 0 (0.0%) 1 (2.0%) n=11 n=6 0 (0.0%) 0 (0.0%) 11 (100.0%) 6 (100.0%) 0 (0.0%) 0 (0.0%) n=4 n=2 0 (0.0%) 0 (0.0%) 4 (100.0%) 2 (100.0%) 0 (0.0%) 0 (0.0%) n=1 n=1 0 (0.0%) 0 (0.0%) 1 (100.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%) HCV-RNART-PCR 357 PEG/R 182 IFN/R 175 24 353 PEG/R 181 IFN/R 172 24 HCV-RNART-PCR 24 PEG/R IFN/R 33.7%61 /181 34.3%59 /172 12 HCV-RNA 619

24 PEG/R IFN/R 0%0 /121 1.7%2 /115 ALT 24 2.7.6-64 24 ALT PEG/R IFN/R 53.9%137 /254 55.6%140 /252 ALT PEG/R -IFN/R 95% -10.37.1% ALT PEG/R IFN/R 70.5%179 /254 65.5%165 /252 ALT PEG/R -IFN/R 95% -3.113.1% ALT 2.7.6-64 ALT C033** PEG/R n=254 IFN/R n=252 * ALT 95% n=254 n=252 179 (70.5%) 165 (65.5%) -3.1% 13.1% 54 (21.3%) 58 (23.0%) 21 (8.3%) 29 (11.5%) 24 n=254 n=252 137 (53.9%) 140 (55.6%) -10.3% 7.1% 71 (28.0%) 58 (23.0%) 46 (18.1%) 54 (21.4%) * PEG/R -IFN/R (CSR 14_2_7_1) PEG/R 2.7.6-65 IFN/R 2.7.6-66 PEG/R 60% 97.2%247 /254 96.5% 245 /254 96.5%245 /254 95.3%242 /254 91.7%233 /254 88.2%224 /254 86.6%220 /254 83.9%213 /254 80.3%204 /254 79.5%202 /254 77.6%197 /254 72.8%185 /254 71.7%182 /254 68.5%174 /254 66.9%170 /254 61.0%155 /254 IFN/R 60% 99.2%251 /253 97.6%247 /253 95.3%241 /253 94.1%238 /253 90.5%229 /253 88.5%224 /253 87.0%220 /253 83.4%211 /253 77.9%197 /253 75.1%190 /253 74.7%189 /253 73.9%187 /253 71.1%180 /253 68.4%173 /253 67.6%171 /253 64.4% 620

163 /253 PEG/R IFN/R 5% PEG/R 41.7%IFN/R 3.6% PEG/R 26.0%IFN/R 2.8% PEG/R 79.5%IFN/R 67.6% PEG/R 86.6% IFN/R 74.7% PEG/R 96.5% IFN/R 87.0% PEG/R 80.3%IFN/R 71.1% PEG/R 27.2%IFN/R 18.2% PEG/R 61.0% IFN/R 52.2% PEG/R 8.3% IFN/R 0.8% PEG/R 21.3%IFN/R 14.6% PEG/R 35.0%IFN/R 29.2% PEG/R 5.9%IFN/R 0.4% PEG/R 8.3% IFN/R 3.2% PEG/R 18.9% IFN/R 13.8% IFN/R PEG/R 5% PEG/R 18.5%IFN/R 30.8% PEG/R 3.9%IFN/R 13.4% PEG/R 33.1%IFN/R 41.9% PEG/R 66.9% IFN/R 75.1% PEG/R 16.1% IFN/R 23.3% PEG/R 6.7% IFN/R 13.0% PEG/R 57.9%IFN/R 64.4% PEG/R 83.9% IFN/R 90.5% PEG/R 35.8%IFN/R 42.3% PEG/R46.1% IFN/R52.6% PEG/R28.0% IFN/R34.4% PEG/R 13.8% IFN/R 19.4% PEG/R 77.6% IFN/R 83.4% PEG/R 5.1% IFN/R 10.3% PEG/R 68.5% IFN/R 73.9% PEG/R 72.8%IFN/R 77.9% PEG/R IFN/R IFN/R PEG/R PEG/R IFN/R 5% PEG/R 19.3%IFN/R 7.1% PEG/R 28.7%IFN/R 17.8% IFN/R PEG/R 5% PEG/R 78.0%198 /254 IFN/R 73.5%186 /253 62.2%158 /254 58.1%147 /253 28.7%73 /254 17.8%45 /253 19.3%49 /254 7.1%18 /253 PEG/R IFN/R PEG/R 2.7.6-67 IFN/R 2.7.6-68 24 25 1 PEG/R 621

36.3 24 27.5 25 6.1 3.5 IFN/R 36.2 27.2 6.1 3.9 24 25 24 5 PEG/R IFN/R IFN 2.7.4.3 24 24 25 PEG/R IFN/R 4 12 25 24 25 PEG/R 24 44.9 114 /254 25 18.8 42 /223 IFN/R 49.0 124 /253 13.1 28 /214 PEG/R 24 4.3 11 /254 25 3.6 8 /223 IFN/R 2.0 5 /253 2.3 5 /214 PEG/R 24 10.6 27 /254 25 8.5 19 /223 IFN/R 12.3 31 /253 7.0 15 /214 24 25 PEG/R 2.7.6-69 IFN/R 2.7.6-70 65 65 40 kg 60 kg 60 kg 80 kg 80 kg 100 kg 622

2.7.6-65 PEG/R C033*1 of 15 PEG/R n=254 2 (0.8%) 54 (21.3%) 198 (78.0%) 254 (100.0%) 19 (7.5%) 7 (2.8%) 0 (0.0%) 26 (10.2%) 16 (6.3%) 4 (1.6%) 0 (0.0%) 20 (7.9%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 5 (2.0%) 47 (18.5%) 7 (2.8%) 2 (0.8%) 56 (22.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 47 (18.5%) 5 (2.0%) 2 (0.8%) 54 (21.3%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 24 (9.4%) 10 (3.9%) 0 (0.0%) 34 (13.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 7 (2.8%) 1 (0.4%) 0 (0.0%) 8 (3.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 12 (4.7%) 4 (1.6%) 0 (0.0%) 16 (6.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 5 (2.0%) 3 (1.2%) 10 (3.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 2 (0.8%) 5 (2.0%) 2 (0.8%) 2 (0.8%) 1 (0.4%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 68 (26.8%) 51 (20.1%) 0 (0.0%) 119 (46.9%) 9 (3.5%) 3 (1.2%) 0 (0.0%) 12 (4.7%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 8 (3.1%) 7 (2.8%) 0 (0.0%) 15 (5.9%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 623

2.7.6-66 IFN/R C033*1 of 15 IFN/R n=253 0 (0.0%) 67 (26.5%) 186 (73.5%) 253 (100.0%) 14 (5.5%) 3 (1.2%) 2 (0.8%) 19 (7.5%) 11 (4.3%) 1 (0.4%) 2 (0.8%) 14 (5.5%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 34 (13.4%) 8 (3.2%) 0 (0.0%) 42 (16.6%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 30 (11.9%) 7 (2.8%) 0 (0.0%) 37 (14.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 24 (9.5%) 10 (4.0%) 1 (0.4%) 35 (13.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 8 (3.2%) 2 (0.8%) 0 (0.0%) 10 (4.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 12 (4.7%) 1 (0.4%) 0 (0.0%) 13 (5.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 13 (5.1%) 1 (0.4%) 15 (5.9%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 4 (1.6%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 5 (2.0%) 1 (0.4%) 6 (2.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 70 (27.7%) 52 (20.6%) 0 (0.0%) 122 (48.2%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 12 (4.7%) 0 (0.0%) 18 (7.1%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 624

2.7.6-65 PEG/R C033*2 of 15 PEG/R n=254 2 (0.8%) 54 (21.3%) 198 (78.0%) 254 (100.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 6 (2.4%) 0 (0.0%) 6 (2.4%) 0 (0.0%) 7 (2.8%) 0 (0.0%) 7 (2.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 2 (0.8%) 0 (0.0%) 17 (6.7%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 5 (2.0%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 4 (1.6%) 0 (0.0%) 8 (3.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 1 (0.4%) 0 (0.0%) 16 (6.3%) 12 (4.7%) 4 (1.6%) 0 (0.0%) 16 (6.3%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 5 (2.0%) 6 (2.4%) 0 (0.0%) 11 (4.3%) 2 (0.8%) 2 (0.8%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 625

2.7.6-66 IFN/R C033*2 of 15 IFN/R n=253 0 (0.0%) 67 (26.5%) 186 (73.5%) 253 (100.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 9 (3.6%) 0 (0.0%) 9 (3.6%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 3 (1.2%) 0 (0.0%) 5 (2.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 27 (10.7%) 6 (2.4%) 0 (0.0%) 33 (13.0%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 4 (1.6%) 0 (0.0%) 7 (2.8%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 18 (7.1%) 1 (0.4%) 0 (0.0%) 19 (7.5%) 17 (6.7%) 0 (0.0%) 0 (0.0%) 17 (6.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 12 (4.7%) 2 (0.8%) 0 (0.0%) 14 (5.5%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 9 (3.6%) 1 (0.4%) 0 (0.0%) 10 (4.0%) 7 (2.8%) 0 (0.0%) 0 (0.0%) 7 (2.8%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 6 (2.4%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 2 (0.8%) 11 (4.3%) 0 (0.0%) 13 (5.1%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 5 (2.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 626

2.7.6-65 PEG/R C033*3 of 15 PEG/R n=254 2 (0.8%) 54 (21.3%) 198 (78.0%) 254 (100.0%) 79 (31.1%) 149 (58.7%) 1 (0.4%) 229 (90.2%) 15 (5.9%) 1 (0.4%) 0 (0.0%) 16 (6.3%) 14 (5.5%) 2 (0.8%) 0 (0.0%) 16 (6.3%) 105 (41.3%) 14 (5.5%) 0 (0.0%) 119 (46.9%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 5 (2.0%) 20 (7.9%) 20 (7.9%) 0 (0.0%) 40 (15.7%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 6 (2.4%) 7 (2.8%) 0 (0.0%) 13 (5.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 19 (7.5%) 40 (15.7%) 0 (0.0%) 59 (23.2%) 57 (22.4%) 27 (10.6%) 0 (0.0%) 84 (33.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 2 (0.8%) 0 (0.0%) 6 (2.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 7 (2.8%) 0 (0.0%) 11 (4.3%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 9 (3.5%) 6 (2.4%) 0 (0.0%) 15 (5.9%) 7 (2.8%) 0 (0.0%) 0 (0.0%) 7 (2.8%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 3 (1.2%) 0 (0.0%) 4 (1.6%) 4 (1.6%) 2 (0.8%) 0 (0.0%) 6 (2.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 8 (3.1%) 0 (0.0%) 9 (3.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 627

2.7.6-66 IFN/R C033*3 of 15 IFN/R n=253 0 (0.0%) 67 (26.5%) 186 (73.5%) 253 (100.0%) 62 (24.5%) 173 (68.4%) 1 (0.4%) 236 (93.3%) 12 (4.7%) 3 (1.2%) 0 (0.0%) 15 (5.9%) 12 (4.7%) 3 (1.2%) 0 (0.0%) 15 (5.9%) bae (41.1%) 25 (9.9%) 0 (0.0%) 129 (51.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 17 (6.7%) 33 (13.0%) 0 (0.0%) 50 (19.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 11 (4.3%) 0 (0.0%) 26 (10.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 4 (1.6%) 0 (0.0%) 5 (2.0%) 13 (5.1%) 49 (19.4%) 0 (0.0%) 62 (24.5%) 70 (27.7%) 36 (14.2%) 0 (0.0%) 106 (41.9%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 3 (1.2%) 0 (0.0%) 6 (2.4%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 4 (1.6%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 2 (0.8%) 7 (2.8%) 0 (0.0%) 9 (3.6%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 7 (2.8%) 0 (0.0%) 22 (8.7%) 8 (3.2%) 0 (0.0%) 0 (0.0%) 8 (3.2%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 3 (1.2%) 0 (0.0%) 4 (1.6%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 628

2.7.6-65 PEG/R C033*4 of 15 PEG/R n=254 2 (0.8%) 54 (21.3%) 198 (78.0%) 254 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 14 (5.5%) 4 (1.6%) 0 (0.0%) 18 (7.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 109 (42.9%) 38 (15.0%) 0 (0.0%) 147 (57.9%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 7 (2.8%) 0 (0.0%) 0 (0.0%) 7 (2.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 4 (1.6%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 29 (11.4%) 0 (0.0%) 44 (17.3%) 30 (11.8%) 26 (10.2%) 0 (0.0%) 56 (22.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8 (3.1%) 10 (3.9%) 0 (0.0%) 18 (7.1%) 28 (11.0%) 7 (2.8%) 0 (0.0%) 35 (13.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 6 (2.4%) 4 (1.6%) 0 (0.0%) 10 (3.9%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 629

2.7.6-66 IFN/R C033*4 of 15 IFN/R n=253 0 (0.0%) 67 (26.5%) 186 (73.5%) 253 (100.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 4 (1.6%) 0 (0.0%) 10 (4.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 109 (43.1%) 54 (21.3%) 0 (0.0%) 163 (64.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8 (3.2%) 0 (0.0%) 0 (0.0%) 8 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 5 (2.0%) 0 (0.0%) 6 (2.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 21 (8.3%) 33 (13.0%) 0 (0.0%) 54 (21.3%) 26 (10.3%) 34 (13.4%) 0 (0.0%) 60 (23.7%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 5 (2.0%) 7 (2.8%) 0 (0.0%) 12 (4.7%) 30 (11.9%) 19 (7.5%) 0 (0.0%) 49 (19.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 7 (2.8%) 0 (0.0%) 11 (4.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 630

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック